top of page
Search

When Early Lyme Disease Is Missed, the Burden Escalates

Writer: Holy Aherns
Holy Aherns
Oct 15
5 min read

Holly and her daughter Kaleigh in Washington DC asking for Congressional support of the 21st Century Cures Act, the legislation that included the language that led to the creation of the HHS TBDWG.
Holly and her daughter Kaleigh in Washington, D.C. asking for Congressional support of the 21st Century Cures Act.

For me, early Lyme disease diagnosis is not an abstract scientific challenge. It is personal.


My daughter, Kaleigh, was a healthy college student and accomplished swimmer when she became seriously ill. Within weeks, she went from competing at an elite level to struggling with overwhelming fatigue, pain and neurological symptoms. We visited doctors and searched for explanations, but Lyme disease was not initially considered—even by me, a microbiologist.


Her experience, recently shared in The Highlands Current’s “War on Ticks” special report, is the reason I understand the importance of early diagnosis from two perspectives: as a scientist and as a mother.


“When my daughter became ill, I learned how short the window for recognizing Lyme disease can be—and how long the consequences of missing it can last. That experience changed the direction of my life and ultimately the work I chose to pursue.”


The Diagnostic Paradox of Early Lyme Disease

The earliest weeks of Lyme disease can be the most important time to identify and treat the infection. They can also be the most difficult.


Early symptoms—including fatigue, fever, headache, muscle pain and joint pain—can resemble many other illnesses. Some patients never notice a tick bite. Others do not develop the characteristic erythema migrans rash, or the rash may be overlooked or mistaken for something else.


Laboratory testing presents an additional challenge. Most Lyme disease tests do not detect the bacteria directly. Instead, they look for antibodies produced by the immune system in response to infection.


According to the Centers for Disease Control and Prevention, it can take several weeks for the immune system to produce enough antibodies to be detected. As a result, antibody tests may appear falsely negative during the first weeks of infection.


This creates a critical diagnostic gray zone: the time when patients may benefit most from an accurate diagnosis is also when current testing may be least sensitive.


For families like mine, that diagnostic gap is not theoretical. It can change the course of a life.


“I often think about that first doctor’s visit and how different my daughter’s story might have been if we had understood the risk and had better diagnostic tools. Families should not have to look back and wonder whether one missed opportunity changed everything.”


What Happens When the Early Window Is Missed?

The CDC reports that patients treated during the early stages of Lyme disease usually recover rapidly and completely. When diagnosis and treatment are delayed, however, the infection may progress and affect the joints, heart and nervous system.


A negative result during the first weeks of illness does not always tell the entire story. The timing of the test must be considered alongside the patient’s symptoms, potential tick exposure, geographic risk and other possible causes of illness.


When early Lyme disease is missed, patients may enter a prolonged cycle of medical appointments, specialist referrals, repeated testing and possible misdiagnosis.


A recent LymeDisease.org report highlights experiences collected through MyLymeData, a patient registry that includes more than 20,000 people affected by Lyme disease.


Among surveyed participants living with chronic or persistent illness:

  • Only 10% reported receiving a Lyme disease diagnosis within the first month.

  • 51% reported seeing seven or more physicians before receiving the correct diagnosis.

  • Only 36% reported a positive Western blot result.


These patient-reported findings do not represent the experience of every person with Lyme disease. They do, however, reveal the human consequences that can accompany a delayed diagnosis.


“When a patient sees seven physicians before receiving the correct diagnosis, that is not simply a statistic. It represents seven appointments, seven explanations and seven moments of hoping someone will finally connect the dots.”


Research has also connected treatment delays with poorer outcomes. In a population-based Pennsylvania study, approximately one-third of Lyme disease patients reported delayed treatment, and those delays were associated with an increased likelihood of post-treatment Lyme disease syndrome. The study was published in Frontiers in Medicine.


The Burden Extends Beyond the Patient

Delayed diagnosis is not simply a matter of waiting longer for an answer. It can mean months or years spent trying to understand unexplained symptoms. Patients may miss work or school, lose the ability to participate in everyday activities and experience significant emotional and financial strain.


Families carry that burden, too. They coordinate appointments, search for specialists, manage mounting medical expenses and advocate for someone whose symptoms may not fit neatly into a single diagnosis.


The healthcare system absorbs the cost of repeated testing, specialist consultations, emergency visits and treatment for conditions a patient may not have.


What begins as one missed diagnostic opportunity can become a much larger burden:


Missed early diagnosis → multiple providers and misdiagnoses → persistent illness and disability → higher healthcare and societal costs


Why I Committed My Work to Better Diagnostics

My daughter’s experience led me to redirect my scientific work toward Lyme disease. I wanted to understand why patients like Kaleigh were being missed and what science could do to prevent other families from following the same painful path.


That mission ultimately helped lead to LymeSeek™.


“I came to Lyme disease first as a mother watching her daughter suffer, and then as a microbiologist determined to understand why patients were being missed. LymeSeek grew from the belief that science can—and must—do better for families facing that same uncertainty.”


Aces Diagnostics is developing LymeSeek, a single-tier multiplex immunoassay designed to improve Lyme disease detection across all stages of infection, including the early diagnostic gray zone.


LymeSeek combines multiple Lyme disease biomarkers with machine-learning analysis to recognize immune-response patterns that traditional approaches may miss. The goal is to provide clinicians with clearer diagnostic information from a single blood sample and help more patients receive answers when those answers can matter most.


LymeSeek begins FDA clinical trials in Fall 2026 and is advancing the test toward regulatory review and an anticipated commercial launch in 2027.


Giving More Families an Earlier Answer

Improving early detection is not about replacing clinical judgment. It is about giving physicians stronger information when a patient’s symptoms and exposure history suggest Lyme disease but existing testing may not yet provide a clear answer.


Better early-stage diagnostics could help reduce false-negative results, support faster treatment decisions, decrease repeated testing and shorten the long journey many patients experience before receiving the correct diagnosis.


I cannot go back and change the beginning of my daughter’s story. But I can work toward changing that story for the patients and families who come next.


“I cannot change what happened to my daughter, but her experience can help shape what happens next. Every patient we help reach earlier is one less person—and one less family—left searching for answers.”


The earliest stage of Lyme disease should not be the stage in which patients are most likely to be missed. By improving detection during this critical window, we have an opportunity to shorten the path to treatment, reduce the burden of delayed diagnosis and give more families the answers they deserve.



This article is intended for educational purposes and does not provide medical advice. Patients should consult a qualified healthcare professional regarding symptoms, testing and treatment.


 
 
 

Comments


  • Instagram
  • LinkedIn
  • Facebook

© 2026 by Aces Diagnostics, Inc.

bottom of page